Desenlaces cardiovasculares en fibrilación auricular y COVID-19 grave en Latinoamérica: registro CARDIO COVID 19-20

Abstract

Introduction y objectivesCardiovascular complications of coronavirus disease 2019 (COVID-19) include various arrhythmias, particularly atrial fibrillation (AF), which has been linked as a risk factor for adverse events, impacting mortality during active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). No studies have investigated this in the Latin American population; thus, we evaluated the impact of a history of AF on intrahospital morbidity and mortality in COVID-19 patients. MethodsA multicenter, retrospective observational analysis was conducted based on the Latin American CARDIO COVID 19-20registry, including COVID-19 patients from 14 Latin American countries. ResultsOf the 3260 SARS-CoV-2-positive patients, 3.5% had a history of AF. This group had a higher prevalence of hypertension (70.4% vs 48.2%; P<.001), heart failure (43.4% vs 4.2%; P<.001), and dyslipidemia (30.4% vs 13.2%; P<.001) than those without AF. Additionally, they had higher values of troponin I (0.03 vs 0.01; P<.001) and NT-proBNP (3045 vs 341.1; P <.001). Cardiovascular complications, such as decompensated heart failure (39.1% vs 7.4%; P<.001) and arrhythmias (40.9% vs 7.9%; P<.001), and in-hospital mortality were more prevalent in the AF group (40.0% vs 25.5%; P<.001). ConclusionsIn Latin America, COVID-19 patients with a history of AF had higher values of cardiac damage biomarkers, more cardiovascular complications, and higher in-hospital mortality.